…
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. Bioxytran, Inc. has collaboration with University of Minnesota for advance novel carbohydrate-based therapeutics. The company was founded in 2008 and is headquartered in Needham, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Bioxytran Inc (BIXT) is limited; filings describe it as a development-stage life sciences company. Long-term growth could depend on advancement of its research and regulatory progress, and securing financing or partnerships, which may attract investors seeking early-stage biotech exposure.
Key risks include limited disclosure, no established revenue, reliance on external funding with dilution risk, development and regulatory uncertainty, and low liquidity on the OTCQB.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -2.12M | -2.38M | -4.56M | -2.66M | -4.53M |
| Minority interest | 0.00M | 0.01M | 0.09M | 0.19M | 0.50M |
| Net income | -2.12M | -2.37M | -4.47M | -2.46M | -4.03M |
| Selling general administrative | 1.39M | 2.11M | 2.65M | 1.16M | 2.20M |
| Reconciled depreciation | 0.01M | 0.01M | 0.01M | 0.00M | - |
| Ebit | - | - | - | - | -4.21M |
| Ebitda | - | - | - | -2.13M | -4.21M |
| Operating income | -1.85M | -2.23M | -3.81M | -2.14M | -4.21M |
| Interest expense | 0.19M | 0.77M | 0.54M | 0.52M | 0.31M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.19M | -0.77M | -0.54M | -0.52M | -0.31M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 1.85M | 2.23M | 3.81M | 2.14M | 4.21M |
| Total other income expense net | -0.08M | 0.62M | -0.21M | - | - |
| Net income from continuing ops | -2.12M | -2.38M | -4.56M | -2.66M | -4.53M |
| Net income applicable to common shares | - | - | - | - | -4.03M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 0.66M | 0.14M | 0.14M | 0.37M | 0.12M |
| Intangible assets | 0.15M | 0.13M | 0.11M | 0.08M | 0.05M |
| Total liab | 3.25M | 1.93M | 3.25M | 3.66M | 3.28M |
| Total stockholder equity | -2.59M | -1.79M | -2.43M | -2.70M | -2.76M |
| Other current liab | 0.50M | 0.41M | 1.03M | 0.04M | 0.11M |
| Common stock | - | - | - | - | 0.11M |
| Capital stock | 0.15M | 0.13M | 0.15M | 0.12M | 0.11M |
| Retained earnings | -21.04M | -18.92M | -15.50M | -11.22M | -8.75M |
| Cash | 0.51M | 0.01M | 0.03M | 0.30M | 0.07M |
| Total current liabilities | 3.25M | 1.93M | 3.25M | 3.66M | 3.28M |
| Net debt | 0.74M | 1.09M | 1.90M | 1.87M | 2.05M |
| Short long term debt | 1.25M | 1.09M | 1.93M | 2.17M | 2.12M |
| Total current assets | 0.51M | 0.01M | 0.03M | 0.30M | 0.07M |
| Net tangible assets | - | - | - | - | -2.81M |
| Accounts payable | 0.00M | 0.00M | 0.00M | 0.00M | 0.53M |
| Non current assets total | 0.15M | 0.13M | 0.11M | 0.08M | 0.05M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.03M | -0.04M | -0.03M | -0.04M |
| Change to liabilities | - | - | - | - | 1.90M |
| Total cashflows from investing activities | - | - | - | - | -0.04M |
| Net borrowings | 0.32M | 0.33M | 0.00M | - | 1.17M |
| Total cash from financing activities | 1.05M | 0.06M | 0.55M | 2.06M | 1.76M |
| Change to operating activities | - | - | - | - | 0.27M |
| Net income | -2.12M | -2.37M | -4.47M | -2.46M | -4.03M |
| Change in cash | 0.50M | -0.02M | -0.27M | 0.22M | 0.03M |
| Begin period cash flow | 0.01M | 0.03M | 0.30M | 0.07M | 0.04M |
| End period cash flow | 0.51M | 0.01M | 0.03M | 0.30M | 0.07M |
| Total cash from operating activities | -0.53M | -0.06M | -0.78M | -1.81M | -1.70M |
| Issuance of capital stock | 0.44M | 0.06M | 0.55M | 0.68M | 0.60M |
| Depreciation | 0.01M | 0.01M | 0.01M | 0.00M | - |
| Other cashflows from financing activities | - | - | - | - | 0.60M |
| Change to netincome | - | - | - | - | 0.09M |
| Capital expenditures | 0.02M | 0.03M | 0.04M | 0.03M | 0.04M |
| Change in working capital | 0.99M | 1.23M | 3.20M | 0.30M | 2.17M |
| Stock based compensation | 0.38M | 0.63M | 0.18M | 0.18M | 0.58M |
| Other non cash items | - | 0.84M | 0.40M | 0.37M | 0.08M |
| Free cash flow | -0.55M | -0.08M | -0.82M | -1.84M | -1.73M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BIXT Bioxytran Inc |
-0.00 15.38% |
0.02 | - | - | 532.56 | 77.85 | 706.64 | -5.72 |
| NVO Novo Nordisk A/S |
-0.54 1.36% |
38.90 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
520.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
2.34 0.25% |
923.34 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. Bioxytran, Inc. has collaboration with University of Minnesota for advance novel carbohydrate-based therapeutics. The company was founded in 2008 and is headquartered in Needham, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. David Platt Ph.D. | Chairman, CEO & Pres | 1953 |
| Mr. Ola Soderquist C.M.A., C.P.A., CM&AA, CMA, CPA, M.B.A. | CFO, Treasurer & Sec. | 1962 |
| Mr. Michael Sheikh B.S. | Exec. VP of Bus. Devel. | 1970 |
| Dr. David Platt Ph.D. | Chairman, CEO & President | 1953 |
| Mr. Ola Soderquist C.M.A., C.P.A., CM&AA, CMA, CPA, M.B.A. | CFO, Treasurer & Secretary | 1962 |
| Mr. Michael Sheikh B.S. | Chief Communication Officer | 1970 |
| Dr. David Platt Ph.D. | Chairman, CEO, President & Secretary | 1953 |
| Mr. Ola Soderquist C.M.A., C.P.A., CM&AA, M.B.A. | CFO & Treasurer | 1962 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.